Supplementary Tables 1-4 and Supplementary Figures S1A and S1B. from Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

Supplemental Table 2: Number of patients in each cohort with any seroreactivity against the candidate antigens (HPV 16,18 E6 and E7) at (A) any timepoint following vaccination and (B) three months following final vaccination Supplemental Table 3: Flow cytometry output frequencies for HPV16 specific CD8+ T cells before and after treatment with MEDI0457 Supplemental Table 4: Flow cytometry output frequencies for HPV18 specific CD8+ T cells before and after treatment with MEDI0457 Supplementary Figure S1A: Flow Cytometry Gating for assessment of CD3+ CD8+ cells Supplementary Figure S1B: Differential expression of CD38, CD69 and CD137 on CD3+ CD8+ cells before and after activation